Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829331 | 0.94 | DRD2 (0.47) | IKBKBMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL13928040 | 0.80 | MEN1 (0.39) | IKBKBMEN1KMT2ADRD2 | |
| SCHEMBL2097203 | 0.80 | IDO1 (0.43) | IKBKBMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL28535227 | 0.79 | MEN1 (0.46) | IKBKBMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL25235310 | 0.78 | CYP2D6 (0.45) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL17304029 | 0.78 | HTR2C (0.50) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL30812563 | 0.78 | KDM4E (0.46) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL1764675 | 0.78 | KDM4E (0.46) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL13451469 | 0.78 | HTR2C (0.50) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL30008129 | 0.78 | KDM4E (0.46) | MEN1KMT2ACYP2D6CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| CN-103059014-B | Novel heteroary aminoderivative | BEIJING HANMEI PHARMACEUTICAL CO., LTD. (CN) | 2016-05-18 | — | — | CN | disclosed |
| CN-103059014-A | Novel heteroaryl amino derivative | BEIJING HANMEI PHARMACEUTICAL CO LTD | 2013-04-24 | — | — | CN | disclosed |
| EP-0119087-B1 | 2-(2-HYDROXY-4-(SUBSTITUTED) PHENYL) PIPERIDINES | PFIZER INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0119087-A1 | 2-(2-Hydroxy-4-(substituted) phenyl) piperidines | PFIZER INC. (US) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | IKBKB 205/4885MEN1 1546/4885KMT2A 4066/4885 |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | IKBKB 205/4885MEN1 1546/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.